COVID-19 Therapeutic Accelerator - ANTICOV - Testing multiple early treatment options for mild COVID-19 infected patients.
- Funded by Foreign, Commonwealth & Development Office (FCDO)
- Total publications:0 publications
Grant number: GB-1-204765-114
Grant search
Key facts
Disease
COVID-19Start & end year
20212023Known Financial Commitments (USD)
$4,903,860.69Funder
Foreign, Commonwealth & Development Office (FCDO)Research Location
SwitzerlandLead Research Institution
Drugs for Neglected Diseases Initiative (DNDi)Research Priority Alignment
N/A
Research Category
Clinical characterisation and managementResearch Subcategory
Supportive care, processes of care and managementSpecial Interest Tags
N/AStudy Type
ClinicalClinical Trial Details
Not applicableBroad Policy Alignment
PendingAge Group
UnspecifiedVulnerable Population
UnspecifiedOccupations of Interest
Unspecified
Abstract
General: Since the beginning of the COVID-19 pandemic, Drugs for Neglected Diseases initiative (DNDi) and its partners have responded on many fronts, its most notable clinical research effort being the ANTICOV trial, which aims to generate data on new early (outpatient) treatment strategies for mild / moderate (according to different definitions) COVID-19 patients in resource-limited settings to reduce the number progressing to severe forms and to relieve the burden on health systems.; General: Since the beginning of the COVID-19 pandemic, Drugs for Neglected Diseases initiative (DNDi) and its partners have responded on many fronts, its most notable clinical research effort being the ANTICOV trial, which aims to generate data on new early (outpatient) treatment strategies for mild / moderate (according to different definitions) COVID-19 patients in resource-limited settings to reduce the number progressing to severe forms and to relieve the burden on health systems.